Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Oncogene, (2023), 10.1038/s41388-022-02585-3)

D. Bello Roufai; A. Gonçalves; T. De La Motte Rouge; S. Akla; C. Blonz; J. Grenier; J. Gligorov; M. Saghatchian; C. Bailleux; H. Simon; I. Desmoulins; Z. Tharin; E. Renaud; M. Bertho; M. A. Benderra; S. Delaloge; L. Robert; P. Cottu; J. Y. Pierga; D. Loirat; A. Bertucci; B. Renouf; F. C. Bidard; F. Lerebours

doi:10.1038/s41388-023-02615-8

Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Oncogene, (2023), 10.1038/s41388-022-02585-3)

D. Bello Roufai, A. Gonçalves, T. De La Motte Rouge, S. Akla, C. Blonz, J. Grenier, J. Gligorov, M. Saghatchian, C. Bailleux, H. Simon, I. Desmoulins, Z. Tharin, E. Renaud, M. Bertho, M. A. Benderra, S. Delaloge, L. Robert, P. Cottu, J. Y. Pierga, D. LoiratA. Bertucci, B. Renouf, F. C. Bidard, F. Lerebours

Research output: Contribution to journal › Comment/debate

Abstract

Correction to: Oncogene, published online 7 January 2023 In this article the affiliation details for Author J. Gligorov were incorrectly given as 7,8,9,10,11,12,13,14, but should have been ‘7, 14’ and for Author J. Y. Pierga were incorrectly given as 1,2,3,4,5,6,7,8,9,10,11,12,13 but should have been 1, 13. In the abstract, the word “data” in the second sentence was misspelled “datda” The original article has been corrected.

Original language	English
Pages (from-to)	1417
Number of pages	1
Journal	Oncogene
Volume	42
Issue number	17
DOIs	https://doi.org/10.1038/s41388-023-02615-8
Publication status	Published - 21 Apr 2023

Access to Document

10.1038/s41388-023-02615-8

Cite this

Bello Roufai, D., Gonçalves, A., De La Motte Rouge, T., Akla, S., Blonz, C., Grenier, J., Gligorov, J., Saghatchian, M., Bailleux, C., Simon, H., Desmoulins, I., Tharin, Z., Renaud, E., Bertho, M., Benderra, M. A., Delaloge, S., Robert, L., Cottu, P., Pierga, J. Y., ... Lerebours, F. (2023). Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Oncogene, (2023), 10.1038/s41388-022-02585-3). Oncogene, 42(17), 1417. https://doi.org/10.1038/s41388-023-02615-8

@article{268f2d74947b435f985ffe1fe22cc367,

title = "Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Oncogene, (2023), 10.1038/s41388-022-02585-3)",

abstract = "Correction to: Oncogene, published online 7 January 2023 In this article the affiliation details for Author J. Gligorov were incorrectly given as 7,8,9,10,11,12,13,14, but should have been {\textquoteleft}7, 14{\textquoteright} and for Author J. Y. Pierga were incorrectly given as 1,2,3,4,5,6,7,8,9,10,11,12,13 but should have been 1, 13. In the abstract, the word “data” in the second sentence was misspelled “datda” The original article has been corrected.",

author = "{Bello Roufai}, D. and A. Gon{\c c}alves and {De La Motte Rouge}, T. and S. Akla and C. Blonz and J. Grenier and J. Gligorov and M. Saghatchian and C. Bailleux and H. Simon and I. Desmoulins and Z. Tharin and E. Renaud and M. Bertho and Benderra, {M. A.} and S. Delaloge and L. Robert and P. Cottu and Pierga, {J. Y.} and D. Loirat and A. Bertucci and B. Renouf and Bidard, {F. C.} and F. Lerebours",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2023",

month = apr,

day = "21",

doi = "10.1038/s41388-023-02615-8",

language = "English",

volume = "42",

pages = "1417",

journal = "Oncogene",

issn = "0950-9232",

number = "17",

}

Bello Roufai, D, Gonçalves, A, De La Motte Rouge, T, Akla, S, Blonz, C, Grenier, J, Gligorov, J, Saghatchian, M, Bailleux, C, Simon, H, Desmoulins, I, Tharin, Z, Renaud, E, Bertho, M, Benderra, MA, Delaloge, S, Robert, L, Cottu, P, Pierga, JY, Loirat, D, Bertucci, A, Renouf, B, Bidard, FC & Lerebours, F 2023, 'Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Oncogene, (2023), 10.1038/s41388-022-02585-3)', Oncogene, vol. 42, no. 17, pp. 1417. https://doi.org/10.1038/s41388-023-02615-8

Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Oncogene, (2023), 10.1038/s41388-022-02585-3). / Bello Roufai, D.; Gonçalves, A.; De La Motte Rouge, T. et al.
In: Oncogene, Vol. 42, No. 17, 21.04.2023, p. 1417.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction

T2 - Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Oncogene, (2023), 10.1038/s41388-022-02585-3)

AU - Bello Roufai, D.

AU - Gonçalves, A.

AU - De La Motte Rouge, T.

AU - Akla, S.

AU - Blonz, C.

AU - Grenier, J.

AU - Gligorov, J.

AU - Saghatchian, M.

AU - Bailleux, C.

AU - Simon, H.

AU - Desmoulins, I.

AU - Tharin, Z.

AU - Renaud, E.

AU - Bertho, M.

AU - Benderra, M. A.

AU - Delaloge, S.

AU - Robert, L.

AU - Cottu, P.

AU - Pierga, J. Y.

AU - Loirat, D.

AU - Bertucci, A.

AU - Renouf, B.

AU - Bidard, F. C.

AU - Lerebours, F.

PY - 2023/4/21

Y1 - 2023/4/21

N2 - Correction to: Oncogene, published online 7 January 2023 In this article the affiliation details for Author J. Gligorov were incorrectly given as 7,8,9,10,11,12,13,14, but should have been ‘7, 14’ and for Author J. Y. Pierga were incorrectly given as 1,2,3,4,5,6,7,8,9,10,11,12,13 but should have been 1, 13. In the abstract, the word “data” in the second sentence was misspelled “datda” The original article has been corrected.

AB - Correction to: Oncogene, published online 7 January 2023 In this article the affiliation details for Author J. Gligorov were incorrectly given as 7,8,9,10,11,12,13,14, but should have been ‘7, 14’ and for Author J. Y. Pierga were incorrectly given as 1,2,3,4,5,6,7,8,9,10,11,12,13 but should have been 1, 13. In the abstract, the word “data” in the second sentence was misspelled “datda” The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85149938405&partnerID=8YFLogxK

U2 - 10.1038/s41388-023-02615-8

DO - 10.1038/s41388-023-02615-8

M3 - Comment/debate

C2 - 36922682

AN - SCOPUS:85149938405

SN - 0950-9232

VL - 42

SP - 1417

JO - Oncogene

JF - Oncogene

IS - 17

ER -

Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Oncogene, (2023), 10.1038/s41388-022-02585-3)

Abstract

Access to Document

Other files and links

Cite this